News

The insulin glargine, which has been co-developed by Mylan and Biocon, is used to treat adults with Type 2 diabetes and adults and paediatric patients with type 1

Again, we are looking to further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro drug development program to be a major pharmaceutical

Researchers from the Massachusetts Institute of Technology (MIT), the University of Brasilia and the University of British Columbia have engineered an antimicrobial peptide that they claim will destroy

The biotechnology company will use the proceeds from financing to accelerate and expand pipeline of oncolytic viral immunotherapies. Turnstone CEO Sammy Farah said: “We are taking a rapid and expansive

Pursuant to its recent End of Phase II meeting with the U.S. Food & Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products, Aurinia believes this Phase

The acquisition includes remetinostat, a skin-directed HDAC inhibitor, and birinapant, a bivalent SMAC mimetic, and all intellectual property and data associated with Tetralogic’s HDAC inhibitor and SMAC mimetic

The deal provides Knudra with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering of model organisms. ERS Genomics holds rights to the foundational

The trial will explore whether the use of the citrate anticoagulant extends the extracorporeal circuit life in acute kidney patients undergoing continuous renal replacement therapy (CRRT). The first

The drug is intended to be used in combination with letrozole as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-)